EGFR Targeted PLGA Nanoparticles Using Gemcitabine for Treatment of Pancreatic Cancer

Authors: Aggarwal, Sahil; Yadav, Sachin; Gupta, Swati

Source: Journal of Biomedical Nanotechnology, Volume 7, Number 1, January 2011 , pp. 137-138(2)

Publisher: American Scientific Publishers

Buy & download fulltext article:

Price: $113.00 plus tax (Refund Policy)

Abstract:

The present study aimed to prepare and characterize anti EGFR monoclonal antibody (mab) conjugated Gemcitabine loaded PLGA nanoparticles for their selective delivery to pancreatic cells and evaluation of the systems in vitro. It was observed that direct covalent coupling of antibodies to glutaraldehyde activated nanoparticles is an appropriate method to achieve cell-type specific drug carrier systems based on polymeric nanoparticles that have potential to be applied for targeted chemotherapy in EGFR positive cancer.

Keywords: ADENOCARCINOMA; ANTI EGFR MONOCLONAL ANTIBODY; GEMCITABINE; PLGA NANOPARTICLES

Document Type: Research article

DOI: http://dx.doi.org/10.1166/jbn.2011.1238

Publication date: 2011-01-01

More about this publication?

Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
Editorial Board
Information for Authors
Subscribe to this Title
Terms & Conditions
ingentaconnect is not responsible for the content or availability of external websites